9Bio

9Bio Therapeutics leverages its AI-guided structural biology platform to design tumour-specific, conditionally active cancer therapeutics. The platform stands out by modelling cancer-associated proteins under the unique biochemical conditions of the tumour microenvironment, which allows 9Bio to develop therapeutics with enhanced cancer specificity. Initially, 9Bio is focusing on high-impact targets such as anti-PD-L1, developed as an antibody-drug conjugate (ADC), as well as a promising tumour antigen that was previously tested as an ADC and demonstrated clinical efficacy but was discontinued due to toxicity. 9Bio’s approach aims to improve both safety and efficacy while accelerating development, providing a strong competitive advantage in the targeted oncology space.